International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Practice Parameter:Immunotherapy for Guillain-Barre Syndrome, Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 61:736-740, Hughes,R.A.C.,et al, 2003
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Acute Encephalitis in Immunocompetent Adults
Lancet 393:702-716, Venkatesan, A.,et al, 2019
Central Nervous System Neuronal Surface Antibody Associated Syndromes: Review and Guidelines for Recognition
JNNP 83:638-645, Zuliani,L.,et al, 2012
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Encephalitis and antibodies to synaptic and neuronal cell surface proteins
Neurol 77:179-189, Lancaster, E.,et al, 2011
Paraneoplastic and Autoimmune Encephalitis
UpToDate, June, Dalmau, J.,et al, 2011
Neurosacrcoidosis: Presentations and Management
Neurologist 16:2-15, Terushkin,V.,et al, 2010
Infectious and Non-Infectious Neurologic Complications in Heart Transplant Recipients
Medicine 89:166-175, Mu�oz,P., et al, 2010